With 0.5 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.42 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.9 whereas the lowest price it dropped to was $2.67. The 52-week range on TRVI shows that it touched its highest point at $4.00 and its lowest point at $0.97 during that stretch. It currently has a 1-year price target of $8.90. Beta for the stock currently stands at 0.98.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TRVI was down-trending over the past week, with a drop of -5.50%, but this was down by -11.86% over a month. Three-month performance dropped to -7.41% while six-month performance fell -0.72%. The stock gained 99.28% in the past year, while it has gained 105.22% so far this year. A look at the trailing 12-month EPS for TRVI yields -0.44 with Next year EPS estimates of -0.49. For the next quarter, that number is -0.12. This implies an EPS growth rate of -67.14% for this year and -2.06% for next year.
Float and Shares Shorts:
At present, 68.28 million TRVI shares are outstanding with a float of 43.76 million shares on hand for trading. On 2024-10-31, short shares totaled 1.72 million, which was 223.0 higher than short shares on 1727654400. In addition to Ms. Jennifer L. Good as the firm’s Co-Founder, CEO, President & Director, Dr. Thomas R. Sciascia M.D. serves as its Co-Founder & Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.80607 of TRVI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, TRVI reported revenue of $0.0 and operating income of -$14087000.0. The EBITDA in the recently reported quarter was -$13236000.0 and diluted EPS was -$0.13.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TRVI since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TRVI analysts setting a high price target of 21.0 and a low target of 6.0, the average target price over the next 12 months is 9.11111. Based on these targets, TRVI could surge 663.64% to reach the target high and rise by 118.18% to reach the target low. Reaching the average price target will result in a growth of 231.31% from current levels.
Analysts have provided yearly estimates in a range of -$0.46492 being high and -$0.49459 being low. For TRVI, this leads to a yearly average estimate of -$0.4847.
